181. First-in-Human Clinical Experience With Focal Pulsed Field and Radiofrequency Dual-Modality Ablation for Treatment Refractory Left Ventricular Summit PVCs.
作者: Shivaraj Patil.;Xiaoke Liu.;Konstantinos C Siontis.;Narut Prasitlumkum.;Samuel J Asirvatham.;Yong-Mei Cha.;Freddy Del-Carpio.;Abhishek J Deshmukh.;Christopher V DeSimone.;Fatima M Ezzeddine.;Paul A Friedman.;Gurukripa N Kowlgi.;Malini Madhavan.;Siva K Mulpuru.;Thomas Munger.;Duy Nguyen.;Peter Noseworthy.;Nicholas Y Tan.;Alan Sugrue.;Suraj Kapa.;Ammar M Killu.
来源: Circ Arrhythm Electrophysiol. 2026年e014942页
Radiofrequency (RF) ablation of premature ventricular complexes (PVCs) originating from the left ventricular summit may be unsuccessful, highlighting the need for alternative approaches. We aimed to assess the efficacy and safety of a novel dual-modality focal catheter in treating left ventricular summit PVCs in patients who had failed previous RF ablation.
182. Maximizing Lesion Depth With the Lattice-Tip Catheter: A Preclinical Comparison of Single, Double, and Mixed Pulsed-Field and Radiofrequency Applications.
作者: Keita Watanabe.;Masaya Shinohara.;Fengyuan Yu.;Vivek Y Reddy.;Jacob S Koruth.
来源: Circ Arrhythm Electrophysiol. 2026年19卷5期e014799页
Combining radiofrequency (RF) and pulsed-field (PF) applications in various combinations, or repeating PF applications, has been reported to augment lesion size and depth. We compared lesion dimensions using single, double, and combined applications of PF and RF for the large-footprint lattice-tip catheter.
183. Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study.
作者: Subbaramireddy Remala.;Liming Liang.;Amil M Shah.;Leo F Buckley.
来源: Circ Genom Precis Med. 2026年e005535页
SGLT2 (sodium-glucose cotransporter-2) inhibitors and GLP-1R (glucagon-like peptide-1 receptor) agonists reduce the risk of major adverse cardiovascular and kidney events in individuals with various cardiometabolic conditions. The long-term efficacy and safety of these therapies, especially in low- and moderate-risk populations, remain uncertain.
184. Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.
作者: Deepak K Gupta.;Lynne W Stevenson.;Erica M Garner.;Christopher Maulion.;Hui Nian.;Patricia R Wright.;Adina F Turcu.;Shouzou Wei.;Nancy J Brown.
来源: Circ Heart Fail. 2026年e014117页
Symptomatic hypotension can limit sacubitril/valsartan therapy. Neprilysin inhibition may augment vasodilators, such as bradykinin. We hypothesized that bradykinin contributes to blood pressure (BP) lowering with sacubitril/valsartan in stable ambulatory patients with heart failure and reduced ejection fraction <50%.
185. Physical Activity in Pediatric Cardiomyopathies: Moving for Health: A Scientific Statement From the American Heart Association.
作者: Jonathan B Edelson.;Carissa M Baker-Smith.;Barbara Cifra.;Melissa Cousino.;Sharlene M Day.;Jonathan A Drezner.;Anne M Dubin.;Corey Gates.;David A White.;Jennifer Conway.; .
来源: Circulation. 2026年153卷21期e1344-e1358页
Physical activity (PA) is essential for the cardiovascular, emotional, and social health of all children and adolescents. However, for pediatric patients with cardiomyopathy, decades of risk-averse clinical guidance have resulted in widespread PA restriction due to fears of sudden cardiac death and disease progression. This has contributed to sedentary behavior, poor cardiorespiratory fitness, and increased risk of secondary cardiometabolic conditions in this population. However, emerging data challenge this restrictive paradigm, showing that the risk of sudden cardiac death may not be higher in some patients with cardiomyopathy who exercise than in those who are less active, and that participation in PA may also have a positive effect on reverse remodeling. This American Heart Association scientific statement provides an evidence-based framework for the promotion of PA in pediatric patients with hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, or arrhythmogenic cardiomyopathy, as well as those with implantable cardioverter defibrillators; outlines the physical, social, and emotional benefits of PA for these children and adolescents; and provides updated risk stratification strategies, including the use of advanced imaging, exercise testing, and genotype-specific data. This scientific statement underscores the importance of shared decision-making tailored to developmental maturity and family goals and emphasizes the need for longitudinal surveillance as clinical phenotypes evolve. With individualized assessment and informed shared decision-making, most children and adolescents with cardiomyopathy can safely engage in PA, with important implications for long-term cardiometabolic and psychologic health.
186. SIRT5 Ameliorates Cardiac Fibrosis via PCK2 Desuccinylation-Mediated Metabolic Reprogramming in Cardiac Fibroblasts.
作者: Maoxiong Wu.;Jing Tan.;Weibin Zhou.;Zenghui Zhang.;Qingyuan Gao.;Yangwei Cai.;Guanghong Liao.;Zhengyu Cao.;Chuanrui Zeng.;Yi Zhang.;Zhiteng Chen.;Qiong Qiu.;Zhaoyu Liu.;Jingfeng Wang.;Haifeng Zhang.;Yangxin Chen.
来源: Circulation. 2026年
SIRT5 (sirtuin 5) is a member of the sirtuin family known to regulate cardiac metabolism, aging, and function. However, its role in cardiac fibroblast (CFB) metabolism, activation, and fibrosis remains elusive.
187. Durability of Bioprosthetic and Mechanical Valves Implanted for Aortic Valve Replacement in Pediatric Patients.
作者: Rumi Yokota.;Yulin Zhang.;Ayush Jaggi.;Tristan Perry.;Elisabeth Martin.;Michael Ma.;Rajesh Punn.;Frank L Hanley.;Doff B McElhinney.
来源: Circ Cardiovasc Interv. 2026年e015931页
There is limited published information on bioprosthetic aortic valve durability. The purpose of this study was to assess the durability of bioprosthetic valves used for aortic valve replacement (AVR) in pediatric patients.
188. Increased Venous Volumes in Response to Catheter-Based Intervention for Acute PE: Lessons From the OPTALYSE PE Trial (OPTALYSE-3D).
作者: Farbod N Rahaghi.;Gregory Piazza.;Behnood Bikdeli.;Umberto Campia.;Syed M Hassan.;Ruben San Jose Estepar.;Michael J Cuttica.;Ruben Mylvaganam.;George R Washko.;Pietro Nardelli.;Samuel Z Goldhaber.;Raúl San José Estépar.
来源: Circ Cardiovasc Imaging. 2026年19卷5期e019239页 189. Initial Experience Using a Variable Loop Circular Pulsed Field Ablation Catheter to Treat Atrial Arrhythmias in Complex Congenital Heart Disease Patients.
作者: Pierre-Olivier Veillette.;Zachariah Hale.;Elizabeth DeWitt.;Douglas Mah.;Thomas Tadros.;Edward O'Leary.
来源: Circ Arrhythm Electrophysiol. 2026年19卷5期e014619页 190. 2026 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (Revision of the 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology): A Report of the ACC Competency Management Committee.
作者: .;José A Joglar.;Julia H Indik.;Nadeen N Faza.;Sana M Al-Khatib.;Sumeet S Chugh.;Edmond Cronin.;James P Daubert.;Jasneet Devgun.;Mehak Dhande.;David S Frankel.;Zachary D Goldberger.;Jodie L Hurwitz.;Fred M Kusumoto.;Dhanunjaya R Lakkireddy.;Amgad N Makaryus.;Joseph E Marine.;Jeremy P Moore.;Kristen K Patton.;Dawn R Phoubandith.;Andrea M Russo.;Rachel Schreier.;Stacy Westerman.
来源: Circ Arrhythm Electrophysiol. 2026年19卷5期e000094页 191. Rare KDR Variants Define a Distinct Genetic Contribution to Congenital Heart Disease.
作者: Feria A Ladha.;Paul Avillach.;Alexander R Opotowsky.;Aldweib Nael.;Martina Brueckner.;Wendy K Chung.;James F Cnota.;Bruce D Gelb.;Matthew Lewis.;Cong Liu.;Amy E Roberts.;Christine E Seidman.;J G Seidman.;Martin Tristani-Firouzi.;Michael Wagner.;Jane W Newburger.;Yuri Kim.;Sarah U Morton.
来源: Circ Genom Precis Med. 2026年e005659页 192. Impact of Virtual Reality on Transcatheter Aortic Valve Implantation: A Prospective Randomized Controlled Trial.
作者: Dominika Kanschik.;Dominik Steinhoff.;Kathrin Klein.;Artur Lichtenberg.;Christina Ballázs.;Dmytro Stadnik.;Maximilian Scherner.;Gerald Antoch.;Malte Kelm.;Tobias Zeus.;Christian Jung.
来源: Circ Cardiovasc Imaging. 2026年e018922页
Accurate preprocedural planning is crucial for a successful transcatheter aortic valve implantation to ensure patient safety and valve longevity. Through 3-dimensional visualization, virtual reality (VR) offers the potential to enhance this process. The study investigated whether the inclusion of VR in preprocedural planning can improve the procedural preparation, impact intraprocedural parameters, and improve short-term patient outcomes.
193. Scalable System-Wide CYP2C19 Pharmacogenomic Testing Reveals 38% Excess Incidence of Adverse Events in Metabolizers Receiving Inappropriate Prescriptions.
作者: Natalie Telis.;Douglas Stoller.;Christopher N Chapman.;C Anwar A Chahal.;Daniel P Judge.;Douglas A Olson.;Joseph J Grzymski.;Catherine Hajek.;Teresa Kruisselbrink.;Nicole L Washington.;Elizabeth T Cirulli.
来源: Circ Genom Precis Med. 2026年e005363页 194. How to Image Myocarditis.
作者: Jan Gröschel.;Bettina Heidecker.;Yashraj Bhoyroo.;Sebastian Spethmann.;Jeanette Schulz-Menger.
来源: Circ Cardiovasc Imaging. 2026年19卷5期e018547页
Myocarditis is an inflammatory disease involving the heart muscle and potentially the pericardium. While there are many potential causative agents, commonly grouped into infectious (viral, bacterial, parasitic) or noninfectious (autoimmune, systemic disorders, drugs, cancer related), the main pathological pathways ultimately lead to an inflammatory process of the myocardium resulting in necrosis and edema. As there are specific therapies available for patients with myocarditis, reliable and early diagnosis is crucial. Multimodality imaging, especially cardiovascular magnetic resonance, has made a noninvasive diagnosis feasible. Cardiovascular magnetic resonance can not only provide a diagnosis based on the updated Lake Louise criteria, but it also functions as a diagnostic gateway, leading to other imaging modalities, for example, positron emission tomography or computed tomography. Finally, imaging results can help to initiate treatment options as well as determine when a patient can return to work or exercise. This review will cover multimodal imaging in patients with myocarditis with a focus on cardiovascular magnetic resonance, providing case examples of how imaging can guide care and treatment in these patients. In addition, the review focuses on the recent European Society for Cardiology guideline on the management of myocarditis and pericarditis comparing the recommendation to the American College of Cardiology expert consensus statements and the Japanese Circulation Society guidelines.
195. Genome-Wide Association Study of Chronic Venous Insufficiency and Lymphedema in the Million Veteran Program.
作者: Gina M Peloso.;Nimish Adhikari.;Melissa M Young.;Kelly Cho.;Scott Kinlay.; .
来源: Circ Genom Precis Med. 2026年e005442页
Lymphedema is a chronic condition characterized by the accumulation of fluid due to impaired lymphatic drainage, frequently occurring secondary to chronic venous insufficiency (CVI), malignancy, or obesity. Despite known environmental and clinical risk factors, the genetic contributors to lymphedema and CVI have been understudied.
196. Biobank-Scale Plasma Proteomics Identifies Novel Biomarkers in Hypertrophic Cardiomyopathy.
作者: Jonathan H Chan.;Christopher Grace.;Mohsen Mazidi.;Robert Clarke.;Carolyn Y Ho.;Stefan Neubauer.;Christopher M Kramer.;Hugh Watkins.;Anuj Goel.; .
来源: Circ Genom Precis Med. 2026年19卷3期e005325页
Hypertrophic cardiomyopathy (HCM) is characterized by substantial heterogeneity in both clinical phenotype and risk of adverse outcomes, including heart failure and sudden cardiac death. This highlights the need for robust biomarkers for risk stratification, and while previous studies have identified the role of select plasma proteins, comprehensive large-scale proteomic analyses have been limited in HCM.
197. Correction to: Microvascular Function and Ambulatory Capacity in Peripheral Artery Disease.
作者: Alexander E Sullivan.;Adam Behroozian.;Crystal Coolbaugh.;Emily Shardelow.;Emily K Smith.;Quinn S Wells.;Daniel G Clair.;Aaron W Aday.;C Louis Garrard.;John A Curci.;Tara A Holder.;Joey V Barnett.;Matthew S Freiberg.;Rachelle L Crescenzi.;Denis J Wakeham.;Christopher M Hearon.;Manus J Donahue.;Joshua A Beckman.
来源: Circ Cardiovasc Interv. 2026年19卷4期e000100页 198. Correction to: Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction.
作者: João Almeida-Coelho.;André M Leite-Moreira.;Vasco Sequeira.;Nazha Hamdani.;André P Lourenço.;Inês Falcão-Pires.;Adelino F Leite-Moreira.
来源: Circ Heart Fail. 2026年19卷4期e000091页 199. Center and Geographic Variability in Acceptance of the First Donor Heart by Race.
作者: Khadijah Breathett.;Shannon M Knapp.;Edward J Bedrick.;Ryan J Tedford.;Shannon M Dunlay.;Selma F Mohammed.;Monica M Colvin.;Richard Daly.
来源: Circ Heart Fail. 2026年19卷4期e013986页
Among accepted US heart organs, listing centers accept organ offers earliest for White women, followed by Black women, White men, and Black men. Understanding the relationships of center- and geographic-level decisions is necessary to understand waitlist disparities. We sought to determine whether listing center and geography are associated with the first heart organ acceptance by candidate race, since race demographics vary regionally across the United States.
200. Ultra-Low-Dose Noise-Free Technology to Reduce Radiation Exposure During Coronary Angiography.
作者: Jinying Zhou.;Qiyu Zhang.;Hao Lu.;Yizhe Wu.;Li Shen.;Jianying Ma.;Rende Xu.;Feng Zhang.;Zhangwei Chen.;Juying Qian.;Chenguang Li.;Junbo Ge.
来源: Circ Cardiovasc Interv. 2026年e016542页
Percutaneous coronary intervention (PCI) is a cornerstone treatment for coronary artery disease. As procedural volumes continue to rise, the associated radiation risk from angiography systems has drawn increasing concern. Thus, we developed a novel ultra-low-dose Noise-Free technology to optimize angiography systems. This study aims to investigate whether it effectively reduces radiation exposure in real-world coronary interventions.
|